India’s 100 million diabetics to benefit from increased access [ and consequent reduction in prices from Rs.60 per tablet to Rs.5.5 per tablet] [2] result of Boehringer Ingelheim drug going off patent earlier this month– Courtesy Business Standard

Leave a Reply